Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1502-1510 |
| Number of pages | 9 |
| Journal | Haematologica |
| Volume | 103 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Cite this
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2. / Barr, PM; Robak, T; Owen, C; Tedeschi, A; Bairey, O; Bartlett, NL; Burger, JA; Hillmen, P; Coutre, S; Devereux, S; Grosicki, S; McCarthy, H; Li, J; Simpson, D; Offner, F; Moreno, C; Zhou, C; Styles, L; James, D; Kipps, TJ; Ghia, P.
In: Haematologica, Vol. 103, No. 9, 2018, p. 1502-1510.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2
AU - Barr, PM
AU - Robak, T
AU - Owen, C
AU - Tedeschi, A
AU - Bairey, O
AU - Bartlett, NL
AU - Burger, JA
AU - Hillmen, P
AU - Coutre, S
AU - Devereux, S
AU - Grosicki, S
AU - McCarthy, H
AU - Li, J
AU - Simpson, D
AU - Offner, F
AU - Moreno, C
AU - Zhou, C
AU - Styles, L
AU - James, D
AU - Kipps, TJ
AU - Ghia, P
PY - 2018
Y1 - 2018
N2 - Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. A total of 269 patients aged ≥65 years with previously untreated chronic lymphocytic leukemia without del(17p) were randomized 1:1 to ibrutinib (n=136) or chlorambucil (n=133) on days 1 and 15 of a 28-day cycle for 12 cycles. Median ibrutinib treatment duration was 28.5 months. Ibrutinib significantly prolonged progression-free survival versus chlorambucil (median, not reached vs. 15 months; hazard ratio, 0.12; 95% confidence interval, 0.07-0.20; P
AB - Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. A total of 269 patients aged ≥65 years with previously untreated chronic lymphocytic leukemia without del(17p) were randomized 1:1 to ibrutinib (n=136) or chlorambucil (n=133) on days 1 and 15 of a 28-day cycle for 12 cycles. Median ibrutinib treatment duration was 28.5 months. Ibrutinib significantly prolonged progression-free survival versus chlorambucil (median, not reached vs. 15 months; hazard ratio, 0.12; 95% confidence interval, 0.07-0.20; P
U2 - 10.3324/haematol.2018.192328
DO - 10.3324/haematol.2018.192328
M3 - Article
VL - 103
SP - 1502
EP - 1510
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 9
ER -